Trial Profile

Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autoimmune-diabetes-vaccine-(Diamyd)-Diamyd-Medical (Primary) ; Colecalciferol (Primary) ; Etanercept (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions
Acronyms EDCR IIa

Most Recent Events

23 Apr 2019 Status changed from active, no longer recruiting to completed.
16 Apr 2019 Results presented in a Diamyd Medical AB Media Release,
27 Mar 2019 According to the Diamyd Medical AB media release, 30 months results from this study are expected to be presented in the spring of 2019

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com